Skip to content
Ontario Rheumatology Association
  • Login
  • Login
  • About
    • Overview
    • Organizational Priorities and Committees
    • Leadership
    • Annual Awards
  • Events
  • EAP & Limited Use Codes
    • Overview
    • Exceptional Access Program
    • EAP Forms and Downloads
    • Limited Use Codes
    • Biosimilar Fact Sheet
    • NIHB Drug List
    • MOHLTC IVIG Request Form
  • Informatics
    • Rheumatology EMR Database at ICES
  • Members
    • Overview
    • Member Directory
    • Peer Mentor Forum
    • Resource for Members
    • Become A Member
    • Renew Membership
    • Membership Perks
  • News
    • Overview
    • Drug Shortages Info
    • Newsletters
    • Other Publications
    • Info Hub
  • Contact
  • Directory
  • Login
  • About
    • Overview
    • Organizational Priorities and Committees
    • Leadership
    • Annual Awards
  • Events
  • EAP & Limited Use Codes
    • Overview
    • Exceptional Access Program
    • EAP Forms and Downloads
    • Limited Use Codes
    • Biosimilar Fact Sheet
    • NIHB Drug List
    • MOHLTC IVIG Request Form
  • Informatics
    • Rheumatology EMR Database at ICES
  • Members
    • Overview
    • Member Directory
    • Peer Mentor Forum
    • Resource for Members
    • Become A Member
    • Renew Membership
    • Membership Perks
  • News
    • Overview
    • Drug Shortages Info
    • Newsletters
    • Other Publications
    • Info Hub
  • Contact
  • Directory

Windshield Wiper Approach to Health Programs and Policy

Denis Morrice • Edition: Winter 2019
Denis Morrice

Windshield Wiper Approach to Health Programs and Policy

You know – Centralize, Decentralize, Centralize, Decentralize. We have been experiencing it with Regional Health Authorities, Regional Health Councils, Community Care Access Centres, Local Health Integrated Networks, OHIP+, Patented Medicines Prices Review Board.

Windshield wiper or “Centralize/Decentralize” programs and policies have an impact on those that deliver direct patient care. The political decisions seem to be made for political reasons and follow political party philosophies or the immediate need regarding election timing.

Rationale:

Decentralize: recognize local needs, local decision making, closer to the people…

Centralize: efficiency, cost effective, central and administrative control …

These supposed high level decisions are made without serious consultation with those most affected by the decision – namely Doctors and Patients. (A simple philosophy to follow: “those affected by a decision should be involved in making that decision”)There doesn’t seem to be any appreciation of the administrative work required at the direct patient care level when these changes are made – nor the impact on access to care.

OHIP+ is a perfect example. The ORA and OPDP reps spent considerable collaborative time on policy development to ensure an effective integration of OHIP+ for youth 25yr and under. Then with a change in government an overnight change was made to scrap OHIP+. So thousands of hours of volunteer and ministry staff time went down the drain. Plus there was zero consultation with Doctors, Parents or youth. Further, the system will add more administrative work for Doctors and their staff and a bureaucratic system that is difficult for many parents to work through.

PMPRB is another very recent example where an incredible amount of consultation with various stakeholders has taken place for over 2 years regarding pricing policies and reference countries. The whole process was put on hold in Nov 2018 and the CEO could not say what the next steps would be. We will probably soon hear that it is back on track.

National Pharmacare is another!

Good luck Dr. Hoskins. Apparently a form of National Pharmacare has been tried 9 times since 1945.

Our ‘Decentralized’ system now has 10 Provincial, 3 Territorial and a number of Federal drug programs with varying degrees of policies and criteria relating to drug access. Plus 100,000 private insurance plans with policies and criteria that are a moving target – especially with specialty drugs e.g. Biologics involving special authorization, co-pays, deductibles, caps, etc.

One thing for sure: the ORA will stay at these policy tables to try and influence the changes in the best interest of Rheumatologists and their patients.

Other Articles in the Winter 2019 Newsletter

  • OMA Section on Rheumatology Report
  • Proposed Changes to OHIP+
  • 2019 ORA Annual Meeting
  • Communications Update
  • RheumOpportunities & Private Payers
Editions
  • Winter 2021
  • Fall 2020
  • Summer 2020
  • Winter 2020
  • Winter 2019
  • Fall 2019
  • Spring 2019
  • Winter 2018
  • Fall 2018
  • Summer 2018
  • Summer 2017
  • Spring 2017
  • Fall 2017
  • Archive
  • Meet the Speakers: ORA 20th Annual Scientific Meeting
Committees
Communications Informatics Models of Care OMA
Tags
Biosimilar CSDTH Models of Care OBRI OMA pCPA SADIE

Contributors

The ORA’s executive members are the core contributors to the newsletter. The ORA welcomes guest contributions to the newsletter from members-at-large and others in the rheumatology community.

Contributors
Ontario Rheumatology Association

© 2020 Ontario Rheumatology Association. All Rights Reserved. Website by Digital Chaos Inc.

  • About
  • Annual Awards
  • Events
  • EAP & Limited Use Codes
  • Exceptional Access Program
  • EAP Forms and Downloads
  • Limited Use Codes
  • Biosimilar Fact Sheet
  • NIHB Drug List
  • MOHLTC IVIG Request Form
  • Informatics
  • Members
  • Member Directory
  • Past Meeting Resources
  • Peer Mentor Forum
  • BecomeA Member
  • Renew Membership
  • News
  • Newsletters
  • Drug Shortages Info
  • Other Publications
  • Info Hub
  • Contact
  • Privacy